Regorafenib (LuciRegor) 40mg*28's | Lucius Laos Generic | GLT

REQUEST A QUOTE

For individuals and institutions — pricing, availability, and product documents (COA) provided within 24 hours.
Direct line: [email protected] · +86 15234153837

Делиться
Product description

Generic Information: LuciRegor (Laos)

LuciRegor is a Laos-market brand of regorafenib manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd., a Lao pharmaceutical company focused on oncology medicines. Each pack contains 28 film-coated tablets of 40 mg. LuciRegor is an accessible option for patients with advanced colorectal cancer, gastrointestinal stromal tumour or hepatocellular carcinoma who need later-line multi-kinase therapy.

What Is Regorafenib (LuciRegor) Used For?

LuciRegor is used to treat metastatic colorectal cancer that has progressed after standard chemotherapy plus anti-VEGF and, where relevant, anti-EGFR therapy. It is also indicated for gastrointestinal stromal tumour resistant to imatinib and sunitinib, and for hepatocellular carcinoma that has progressed on sorafenib. It is a later-line disease-control therapy given once earlier treatments have stopped working.

How Does Regorafenib Work?

Regorafenib is a multi-kinase inhibitor that blocks the VEGF receptors 1, 2 and 3, TIE2, PDGFR-α and β, FGFR-1 and 2, KIT, RET, RAF-1 and BRAF. This broad action suppresses both the growth signals inside cancer cells and the signalling that drives new blood-vessel formation, so tumours are deprived of both the instructions to divide and the blood supply they need to survive and spread.

Indications

The three approved indications are advanced colorectal cancer after prior standard therapy, imatinib- and sunitinib-resistant gastrointestinal stromal tumour, and sorafenib-refractory hepatocellular carcinoma. An oncologist should initiate and monitor treatment, and liver function and blood pressure must be assessed before starting.

Dosage

The recommended dose is 160 mg (four 40 mg tablets) once daily with a low-fat meal, given in 28-day cycles of 21 days on and 7 days off. A 28-tablet pack supplies seven days of the active-treatment phase. The dose may be reduced to 120 mg or 80 mg daily to manage side effects such as hand-foot skin reaction or elevated liver enzymes.

Side Effects

The most frequent side effects are hand-foot skin reaction, diarrhoea, fatigue, high blood pressure, reduced appetite and mouth sores. Serious but uncommon effects include liver injury, bleeding, gastrointestinal perforation and cardiac problems. Liver function, blood pressure and blood counts should be monitored regularly, and patients should report skin changes, persistent diarrhoea, dark stools or chest pain promptly.

Storage

Store LuciRegor tablets at room temperature in the original container, protected from moisture, and out of the reach of children. Do not use past the expiry date on the pack.

Why Choose LuciRegor Through GLT?

LuciRegor provides overseas patients and institutions with a lower-cost regorafenib sourced from the Lao market, where manufacturing keeps pricing accessible. GLT verifies authenticity and ships worldwide from a Hong Kong-licensed facility, giving patients a dependable and affordable supply for longer-term later-line cancer treatment.

How to Order

To order LuciRegor (regorafenib) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We will confirm current availability, pricing and delivery to your country, and we ship from a Hong Kong-licensed facility.

FAQ

Is LuciRegor the same as Stivarga? Yes — it contains the same regorafenib molecule, manufactured by Lucius Pharmaceuticals in Laos.

What is the dosing schedule? 160 mg once daily for 21 days, then a 7-day break, repeated every 28 days.

Do I need a prescription? Yes, regorafenib is prescription-only and requires a valid oncologist's prescription.

Related Oncology Products

Rizonib (Кризотиниб) 250 мг капсулы | Дженерик Xalkori из Бангладеш (DIL) для ALK+ НМРЛ | GLT

Rizonib 250 от Drug International Ltd (DIL), Тонги Газипур — доступный дженерик кризотиниба из Бангладеш

Орфорглипрон (OriYo) 0,8–17,2 мг таблетки | Бангладешский дженерик пероральный GLP-1 | GLT

Дженерик орфорглипрона от National Drug Co. (Бангладеш), 6-ступенчатая титрация для контроля веса

Barinib (Барицитиниб) 2мг | Дженерик-ингибитор JAK1/JAK2 | Drug International Limited | GLT

Дженерик барицитиниба (ингибитора JAK1/JAK2) от Drug International Limited (Бангладеш) — доступная альтернатива Olumiant при ревматоидном...

Орфорглипрон (LuciOrfor) 0,8–17,2 мг таблетки | Лаосский дженерик пероральный GLP-1 | GLT

Дженерик орфорглипрона от Lucius Pharmaceuticals (Лаос), 6-ступенчатая схема титрования для контроля веса

KangQuXin 康曲欣 (Аватромбопаг) 20 мг × 10 таблеток | Beijing Continent (Gyre) | GLT

KangQuXin — аватромбопаг от Beijing Continent Pharmaceutical (Gyre Therapeutics, Nasdaq: GYRE), Китай

KeZeRui 科瑞泽 (Аватромбопаг) 20мг*10 таб. | Sichuan Kelun (Китай) | GLT

KeZeRui — аватромбопаг национальной закупки от Sichuan Kelun Pharmaceutical, интегрированного китайского производителя АФС и таблеток.

Olumiant (Барицитиниб) таблетки 2мг/4мг | Ингибитор JAK1/JAK2 | Eli Lilly (США) | GLT

Селективный ингибитор JAK1/JAK2 компании Eli Lilly для лечения ревматоидного артрита, атопического дерматита и тяжёлой очаговой...

Baricent (Барицитиниб) 2мг | Дженерик-ингибитор JAK1/JAK2 | Incepta Pharmaceuticals Ltd. | GLT

Дженерик барицитиниба (ингибитора JAK1/JAK2) от Incepta Pharmaceuticals Ltd. (Бангладеш) — доступная альтернатива Olumiant при ревматоидном...